The emerging role of rituximab in autoimmune blistering diseases

AR Ahmed, S Shetty - American Journal of Clinical Dermatology, 2015 - Springer
Rituximab is a chimeric monoclonal antibody that selectively binds to the CD20 molecule on
B cells, resulting in their lysis. In autoimmune blistering diseases, the auto-antibody …
被引用次数：20 相关文章

The Emerging Role of Rituximab in Autoimmune Blistering Diseases.

A Ahmed, S Shetty - American Journal of Clinical …, 2015 - search.ebscohost.com
Rituximab is a chimeric monoclonal antibody that selectively binds to the CD20 molecule on
B cells, resulting in their lysis. In autoimmune blistering diseases, the auto-antibody …

The Emerging Role of Rituximab in Autoimmune Blistering Diseases

AR Ahmed, S Shetty - American Journal of Clinical Dermatology, 2015 - infona.pl
Rituximab is a chimeric monoclonal antibody that selectively binds to the CD20 molecule on
B cells, resulting in their lysis. In autoimmune blistering diseases, the auto-antibody …

The emerging role of rituximab in autoimmune blistering diseases

AR Ahmed, S Shetty - American journal of clinical …, 2015 - pubmed.ncbi.nlm.nih.gov
Rituximab is a chimeric monoclonal antibody that selectively binds to the CD20 molecule on
B cells, resulting in their lysis. In autoimmune blistering diseases, the auto-antibody …

The emerging role of rituximab in autoimmune blistering diseases.

AR Ahmed, S Shetty - American Journal of Clinical Dermatology, 2015 - europepmc.org
Rituximab is a chimeric monoclonal antibody that selectively binds to the CD20 molecule on
B cells, resulting in their lysis. In autoimmune blistering diseases, the auto-antibody …